China
· Delayed Price · Currency is CNY Cathay Biotech Statistics
Total Valuation
Cathay Biotech has a market cap or net worth of CNY 33.96 billion. The enterprise value is 28.38 billion.
| Market Cap | 33.96B |
| Enterprise Value | 28.38B |
Important Dates
The next estimated earnings date is Thursday, August 14, 2025.
| Earnings Date | Aug 14, 2025 |
| Ex-Dividend Date | Jul 24, 2024 |
Share Statistics
Cathay Biotech has 720.66 million shares outstanding. The number of shares has increased by 0.07% in one year.
| Current Share Class | 720.66M |
| Shares Outstanding | 720.66M |
| Shares Change (YoY) | +0.07% |
| Shares Change (QoQ) | +3.87% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 17.77% |
| Float | 251.86M |
Valuation Ratios
The trailing PE ratio is 52.93 and the forward PE ratio is 66.38.
| PE Ratio | 52.93 |
| Forward PE | 66.38 |
| PS Ratio | 11.14 |
| PB Ratio | 1.61 |
| P/TBV Ratio | 2.01 |
| P/FCF Ratio | 1,019.00 |
| P/OCF Ratio | 49.00 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 39.04, with an EV/FCF ratio of 851.57.
| EV / Earnings | 54.52 |
| EV / Sales | 9.31 |
| EV / EBITDA | 39.04 |
| EV / EBIT | 70.33 |
| EV / FCF | 851.57 |
Financial Position
The company has a current ratio of 5.10, with a Debt / Equity ratio of 0.08.
| Current Ratio | 5.10 |
| Quick Ratio | 4.46 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | 2.22 |
| Debt / FCF | 49.08 |
| Interest Coverage | 16.87 |
Financial Efficiency
Return on equity (ROE) is 2.73% and return on invested capital (ROIC) is 1.31%.
| Return on Equity (ROE) | 2.73% |
| Return on Assets (ROA) | 1.19% |
| Return on Invested Capital (ROIC) | 1.31% |
| Return on Capital Employed (ROCE) | 1.87% |
| Revenue Per Employee | 1.76M |
| Profits Per Employee | 300,088 |
| Employee Count | 1,735 |
| Asset Turnover | 0.14 |
| Inventory Turnover | 1.69 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -2.38% in the last 52 weeks. The beta is 0.62, so Cathay Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.62 |
| 52-Week Price Change | -2.38% |
| 50-Day Moving Average | 50.02 |
| 200-Day Moving Average | 44.50 |
| Relative Strength Index (RSI) | 36.28 |
| Average Volume (20 Days) | 2,322,428 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Cathay Biotech had revenue of CNY 3.05 billion and earned 520.65 million in profits. Earnings per share was 0.89.
| Revenue | 3.05B |
| Gross Profit | 901.02M |
| Operating Income | 413.47M |
| Pretax Income | 582.26M |
| Net Income | 520.65M |
| EBITDA | 736.94M |
| EBIT | 413.47M |
| Earnings Per Share (EPS) | 0.89 |
Balance Sheet
The company has 10.80 billion in cash and 1.64 billion in debt, giving a net cash position of 9.16 billion or 12.71 per share.
| Cash & Cash Equivalents | 10.80B |
| Total Debt | 1.64B |
| Net Cash | 9.16B |
| Net Cash Per Share | 12.71 |
| Equity (Book Value) | 21.15B |
| Book Value Per Share | 29.50 |
| Working Capital | 10.41B |
Cash Flow
In the last 12 months, operating cash flow was 693.14 million and capital expenditures -659.81 million, giving a free cash flow of 33.33 million.
| Operating Cash Flow | 693.14M |
| Capital Expenditures | -659.81M |
| Free Cash Flow | 33.33M |
| FCF Per Share | 0.05 |
Margins
Gross margin is 29.55%, with operating and profit margins of 13.56% and 17.08%.
| Gross Margin | 29.55% |
| Operating Margin | 13.56% |
| Pretax Margin | 19.10% |
| Profit Margin | 17.08% |
| EBITDA Margin | 24.17% |
| EBIT Margin | 13.56% |
| FCF Margin | 1.09% |
Dividends & Yields
This stock pays an annual dividend of 0.40, which amounts to a dividend yield of 0.85%.
| Dividend Per Share | 0.40 |
| Dividend Yield | 0.85% |
| Dividend Growth (YoY) | 5.56% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 27.48% |
| Buyback Yield | -0.07% |
| Shareholder Yield | 0.79% |
| Earnings Yield | 1.53% |
| FCF Yield | 0.10% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 20, 2022. It was a forward split with a ratio of 1.4.
| Last Split Date | Jul 20, 2022 |
| Split Type | Forward |
| Split Ratio | 1.4 |
Scores
Cathay Biotech has an Altman Z-Score of 5.14.
| Altman Z-Score | 5.14 |
| Piotroski F-Score | n/a |